Skip to main content
Top

Oncology and Therapy

2013 - 2024
Volumes
22
Issues
Chevron right icon
Issue 1/2024
Latest issue

Oncology and Therapy OnlineFirst articles

About this journal

Oncology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad, dedicated to the publication of high-quality clinical, observational, real-world, patient care, and health outcomes research around the discovery, development, and use of therapeutics and interventions across all areas of oncology. The key features of the journal are:

Rapid publication: The journal aims for a 2-week peer review, 3-4 weeks from acceptance to online.
Open access: All articles published open access (CC-BY-NC)
Inclusivity: All scientifically sound research considered be it positive, confirmatory or negative data. Research is considered from pre-clinical, clinical phase, real-world and health economics outcomes studies. Submissions are welcomed whether they relate to an international or a country-specific audience.
Personal service: The journal’s team will re-format articles and upload submissions on behalf of authors, if necessary.
Digital Features and Plain Language Summaries: These peer-reviewed features are welcomed to help enhance the educational value of a manuscript (for more information see “Author Information – Guidelines for digital features and plain language summaries” under “Submission guidelines”).
Publication fees: Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €4500/ $5600/ £4100. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. If you would like to request a discount or waiver please do so either ahead of submission or at the very start of the submission process. Requests made after this stage will not be considered.

Metadata
Title
Oncology and Therapy
Coverage
Volume 1/2013 - Volume 12/2024
Publisher
Springer Healthcare
Electronic ISSN
2366-1089
Print ISSN
2366-1070
Journal ID
40487
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine